Current Opinion in HIV and AIDS was launched in 2006. It is one of a successful series of review journals whose unique format is designed to provide a systematic and critical assessment of the literature as presented in the many primary journals. The fields of HIV and AIDS are divided into nine sections that are reviewed once a year. Each section is assigned a Section Editor, a leading authority in the area, who identifies the most important topics at that time. Here we are pleased to introduce the Section Editor for this issue.
Amalio Telenti is a research scientist at the Genome Medicine group, J. Craig Venter Institute in La Jolla, California, USA, and head of functional biology at Human Longevity Inc., a genomics company, also in La Jolla. Previous to these appointments he was Professor and Director at the Institute of Microbiology, University Hospital of Lausanne, in Switzerland. He is a graduate in medicine of the University of Oviedo, Spain, trained in internal medicine and infectious diseases at the Mayo Clinic, in Rochester, Minnesota, USA (American Board Certified), and in microbiology at the University of Bern, Switzerland. In addition to the MD degree, he holds a PhD in microbiology from the University of Zaragoza, Spain.
Amalio Telenti research career has focused on the host genetic determinants of susceptibility to HIV infection. He chaired a large genetic core project of the Swiss HIV Cohort Study, and coordinated the genetic project of CHAVI (Center for HIV/AIDS vaccine immunology) that allowed the conclusion of the first genome-wide association study in HIV. He conducted various large-scale transcriptome studies, including the comparative analysis of primate expression responses to HIV. These and recent work were pivotal to formalizing the study of human tolerance to HIV infection. He has used evolutionary genomics in the study of restriction factors and host dependency factors, including the innovative use of ancestral reconstruction techniques to describe plausible evolutionary trajectories of antiviral capacity of restriction factors in primate genomes. More recently, he has applied systems approaches to the study of cellular responses to infection and in primary cell models of latency.
Amalio Telenti searched practical applications of genetic data though the implementation of pharmacogenetics. His laboratory described genetic variants affecting metabolism of several antiretroviral agents, and worked with pharmacologists to develop population pharmacokinetic-pharmacogenetic modeling of HIV treatment and toxicity. He is now testing the delivery and acceptance of pharmacogenetic data in the clinics. Previous to working on HIV, he identified the molecular basis of resistance to three of the main antituberculosis drugs (rifampin, ethambutol and fluoroquinolones). This work is the basis of current and widely used molecular diagnostic tests of tuberculosis drug resistance.
Amalio Telenti is part of the editorial board of several pharmacogenetic journals and associate editor for pre-clinical research in Antiviral Therapy. He is member of the scientific advisor board for various national and international agencies, conferences, including CROI, the French ANRS (National Agency for research on HIV and Hepatitis), the German DZIF (Center of Infection Research), and research programs at the Ragon Institute of MSG, MIT and Harvard. He has received numerous scientific distinctions, including the Cloetta Foundation award, one of the highest distinctions in medicine in Switzerland. He is an elected member of the Swiss Academy of Medical Sciences. In addition to his contributions to research, Amalio Telenti has provided medical care to people living with HIV since the beginning of the AIDS epidemic.